<< Вернуться к списку статей журнала

Том 15 №1 2013 год - Нефрология и диализ

Практические Клинические рекомендации KDIGO по анемии при хронической болезни почек 2012

Аннотация: Перевод с английского А.Ю. Земченкова под редакцией Е.В. Захаровой Перевод выполнен по поручению и одобрен KDIGO Клинические практические рекомендации KDIGO по анемии при хронической болезни почек (ХБП) 2012 г. имеют своей целью обспечить необходимую информацию для диагностики, оценки, ведения и лечения всех пациентов с ХБП (детей и взрослых на до-диализной стадии, на диализе и после трансплантации почки) с анемией или риском развития анемии. Формированию рекомендаций предшествовал длительный процесс сбора и оценки доказательств. Рекомендации содержат главы, касающиеся диагностики и оценки анемии при ХБП и использования различных терапевтических средств (препаратов железа, эритропоэз-стимулирующих средств и др.) и гемотрансфузий как методов лечения анемии. Подходы к лечению рассмотрены в отдельных главах, рекомендации основаны на систематическом обзоре соответствующих исследований. Оценка качества доказательности и силы рекомендаций построена на системе присвоения СТЕПЕНЕЙ. Обсуждаются противоречия и органичения доказательности, приводятся предложения по проведению дальнейших исследований. Члены рабочей группы Председатели рабочей группы Джон МакМюррей, Великобритания; Патрик Пэрфри, Канада Рабочая группа Джон Адамсон, США; Педро Альяма, Испания; Джеффри Бернс, США; Джулия Болиус, Швейцария; Тильман Дрюке, Франция; Фредерик Финкельштейн, США; Стивен Фишдейн, США; Томас Ганц, США; Йен Макдугал, Великобритания; Рут Макдоналд, США; Лоренс МакМагон, Австралия; Грегорио Обрадор, Мексика; Джованни Стрипполи, Италия; Гюнтер Вейсс, Австрия; Анджей Виечек, Польша Цитирование: при цитировании этого документа следует необходимо соблюдать следующий формат: Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter ., Suppl . 2012; 2: XXX–XXX.

Для цитирования: Практические Клинические рекомендации KDIGO по анемии при хронической болезни почек 2012. Нефрология и диализ. 2013. 15(1):14-53. doi:

Весь текст

Ключевые слова: анемия при ХБП, Клинические практические рекомендации, эритропоэз-стимулирующие средства, KDIGO, Рекомендации, основанные на доказательствах, железо, систематический обзор, Anemia in CKD, Clinical practice guideline, erythropoiesis-stimulating agent, KDIGO, evidence-based recommendation, iron, systematic review

Список литературы:

1. Astor B.C., Muntner P., Levin A. et al. Association of kidney function withanemia: the Third National Health and Nutrition Examination Survey (1988–1994) // Arch Intern Med. 2002. Vol. 162. P. 1401–1408.
2. Fadrowski J.J., Pierce C.B., Cole S.R. et al. Hemoglobin decline in childrenwith chronic kidney disease: baseline results from the chronic kidneydisease in children prospective cohort study // Clin. J. Am. Soc. Nephrol. 2008. Vol. 3. P. 457–462.
3. Schwartz G.J., Munoz A., Schneider M.F. et al. New equations to estimateGFR in children with CKD // J. Am. Soc. Nephrol. 2009. Vol. 20. P. 629–637.
4. World Health Organization. Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia. In: de Benoist B., McLean E., Egli Iand M Cogswell (eds). 2008.
5. Hollowell J.G., van Assendelft O.W., Gunter E.W. et al. Hematological andiron-related analytes–reference data for persons aged 1 year and over: United States, 1988–94. Vital Health Stat. 2005. Vol. 11. P. 1–156.
6. Nathan D.G., Orkin S.H. Appendix 11: Normal hematologic values inchildren. In: Nathan D.G., Orkin S.H., Ginsburg D., Look A.T., Oski F.A. (eds).Nathan and Oski’s Hematology of Infancy and Childhood, 6th edn. WB Saunders. Philadelphia, PA, 2003. P. 1841.
7. Brittin G.M., Brecher G., Johnson C.A. et al. Stability of blood in commonlyused anticoagulants. Use of refrigerated blood for quality control of the Coulter Counter Model S // Am. J. Clin. Pathol. 1969. Vol. 52. P. 690–694.
8. Locatelli F., Aljama P., Barany P. et al. Revised European best practiceguidelines for the management of anaemia in patients with chronicrenal failure // Nephrol Dial Transplant. 2004. Vol. 19 (Suppl 2). ii1–i47.
9. Morris M.W., Davey F.R. Basic examination of blood. Clinical Diagnosis andManagement by Laboratory Methods. WB Saunders. 1996. pp. 549–593.
10. Weiss G., Goodnough L.T. Anemia of chronic disease // N Engl J Med. 2005. Vol. 352. P. 1011–1023.
11. Fehr T., Ammann P., Garzoni D. et al. Interpretation of erythropoietinlevels in patients with various degrees of renal insufficiency and anemia // Kidney Int. 2004. Vol. 66. P. 1206–1211.
12. Ross R.P., McCrea J.B., Besarab A. Erythropoietin response to blood loss inhemodialysis patients in blunted but preserved // ASAIO J. 1994. Vol. 40. M880–M885.
13. Lipschitz D.A., Cook J.D., Finch C.A. A clinical evaluation of serum ferritin asan index of iron stores // N Engl J Med. 1974. Vol. 290. P. 1213–1216.
14. Rambod M., Kovesdy C.P., Kalantar-Zadeh K. Combined high serumferritin and low iron saturation in hemodialysis patients: the role ofinflammation // Clin. J. Am. Soc. Nephrol. 2008. Vol. 3. P. 1691–1701.
15. Fernandez-Rodriguez A.M., Guindeo-Casasus M.C., Molero-Labarta T. et al. Diagnosis of iron deficiency in chronic renal failure // Am J Kidney Dis. 1999. Vol. 34. P. 508–513.
16. Kalantar-Zadeh K., Hoffken B., Wunsch H. et al. Diagnosis of irondeficiency anemia in renal failure patients during the posterythropoietinera // Am J Kidney Dis. 1995. Vol. 26. P. 292–299.
17. Aljama P., Ward M.K., Pierides A.M. et al. Serum ferritin concentration: areliable guide to iron overload in uremic and hemodialyzed patients // Clin Nephrol. 1978. Vol. 10. P. 101–104.
18. Barany P., Eriksson L.C., Hultcrantz R. et al. Serum ferritin and tissue iron inanemic dialysis patients // Miner Electrolyte Metab. 1997. Vol. 23. P. 273–276.
19. Blumberg A.B., Marti H.R., Graber C.G. Serum ferritin and bone marrow ironin patients undergoing continuous ambulatory peritoneal dialysis // JAMA. 1983. Vol. 250. P. 3317–3319.
20. Hussein S., Prieto J., OoShea M. et al. Serum ferritin assay and iron status inchronic renal failure and haemodialysis // Br Med J. 1975. Vol. 1. P. 546–548.
21. Mirahmadi K.S., Paul W.L., Winer R.L. et al. Serum ferritin level. Determinantof iron requirement in hemodialysis patients // JAMA. 1977. Vol. 238. P. 601–603.
22. Tessitore N., Girelli D., Campostrini N. et al. Hepcidin is not useful as abiomarker for iron needs in haemodialysis patients on maintenanceerythropoiesis-stimulating agents // Nephrol Dial Transplant. 2010. Vol. 25. P. 3996–4002.
23. Tessitore N., Solero G.P., Lippi G. et al. The role of iron status markers inpredicting response to intravenous iron in haemodialysis patients onmaintenance erythropoietin // Nephrol Dial Transplant. 2001. Vol. 16. P. 1416–1423.
24. Galloway M., Rushworth L. Red cell or serum folate? Results from theNational Pathology Alliance benchmarking review // J Clin Pathol. 2003. Vol. 56. P. 924–926.
25. Mircescu G., Garneata L., Capusa C. et al. Intravenous ironsupplementation for the treatment of anaemia in pre-dialyzed chronicrenal failure patients // Nephrol Dial Transplant. 2006. Vol. 21. P. 120–124.
26. Silverberg D.S., Iaina A., Peer G. et al. Intravenous iron supplementation forthe treatment of the anemia of moderate to severe chronic renal failurepatients not receiving dialysis // Am J Kidney Dis. 1996. Vol. 27. P. 234–238.
27. Fishbane S., Frei G.L., Maesaka J. Reduction in recombinant humanerythropoietin doses by the use of chronic intravenous ironsupplementation // Am J Kidney Dis. 1995. Vol. 26. P. 41–46.
28. Sunder-Plassmann G., Horl W.H. Importance of iron supply forerythropoietin therapy // Nephrol Dial Transplant. 1995. Vol. 10. P. 2070–2076.
29. Fishbane S., Maesaka J.K. Iron management in end-stage renal disease // Am J Kidney Dis. 1997. Vol. 29. P. 319–333.
30. Fishbane S., Kowalski E.A., Imbriano L.J. et al. The evaluation of iron statusin hemodialysis patients // J Am SocNephrol. 1996. Vol. 7. P. 2654–2657.
31. Fishbane S., Shapiro W., Dutka P. et al. A randomized trial of irondeficiency testing strategies in hemodialysis patients // Kidney Int. 2001. Vol. 60. P. 2406–2411.
32. Macdougall I.C., Tucker B., Thompson J. et al. A randomized controlledstudy of iron supplementation in patients treated with erythropoietin // Kidney Int. 1996. Vol. 50. P. 1694–1699.
33. Feldman H.I., Joffe M., Robinson B. et al. Administration of parenteral ironand mortality among hemodialysis patients // J Am SocNephrol. 2004. Vol. 15. P. 1623–1632.
34. Feldman H.I., Santanna J., Guo W. et al. Iron administration and clinicaloutcomes in hemodialysis patients // J. Am. Soc.Nephrol. 2002. Vol. 13. P. 734–744.
35. Kalantar-Zadeh K., Regidor D.L., McAllister C.J. et al. Time-dependentassociations between iron and mortality in hemodialysis patients // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 3070–3080.
36. Chang C.H., Chang C.C., Chiang S.S. Reduction in erythropoietin doses bythe use of chronic intravenous iron supplementation in iron-repletehemodialysis patients // ClinNephrol. 2002. Vol. 57. P. 136–141.
37. Senger J.M., Weiss R.J. Hematologic and erythropoietin responses to irondextran in the hemodialysis environment // ANNA J. 1996. Vol. 23. P. 319–323. discussion 324–315.
38. Spinowitz B.S., Kausz A.T., Baptista J. et al. Ferumoxytol for treating irondeficiency anemia in CKD // J. Am. Soc. Nephrol. 2008. Vol. 19. P. 1599–1605.
39. Silverberg D.S., Blum M., Agbaria Z. et al. The effect of i.v. iron alone or incombination with low-dose erythropoietin in the rapid correction ofanemia of chronic renal failure in the predialysis period // Clin Nephrol. 2001. Vol. 55. P. 212–219.
40. Stancu S., Barsan L., Stanciu A. et al. Can the response to iron therapy bepredicted in anemic nondialysis patients with chronic kidney disease? // Clin. J. Am. Soc. Nephrol. 2010. Vol. 5. P. 409–416.
41. Besarab A., Kaiser J.W., Frinak S. A study of parenteral iron regimens inhemodialysis patients // Am J Kidney Dis. 1999. Vol. 34. P. 21–28.
42. DeVita M.V., Frumkin D., Mittal S. et al. Targeting higher ferritinconcentrations with intravenous iron dextran lowers erythropoietinrequirement in hemodialysis patients // Clin Nephrol. 2003. Vol. 60. P. 335–340.
43. Navarro J.F., Teruel J.L., Liano F. et al. Effectiveness of intravenousadministration of Fe-gluconate-Na complex to maintain adequate bodyiron stores in hemodialysis patients // Am J Nephrol. 1996. Vol. 16. P. 268–272.
44. Anker S.D., Comin Colet J., Filippatos G. et al. Ferric carboxymaltose inpatients with heart failure and iron deficiency // N Engl J Med. 2009. Vol. 361. P. 2436–2448.
45. Van Wyck D.B., Roppolo M., Martinez C.O. et al. A randomized, controlledtrial comparing IV iron sucrose to oral iron in anemic patients withnondialysis-dependent CKD // Kidney Int. 2005. Vol. 68. P. 2846–2856.
46. Ford B.A., Coyne D.W., Eby C.S. et al. Variability of ferritin measurements inchronic kidney disease; implications for iron management // Kidney Int. 2009. Vol. 75. P. 104–110.
47. Fishbane S. Upper limit of serum ferritin: misinterpretation of the 2006KDOQI anemia guidelines // Semin Dial. 2008. Vol. 21. P. 217–220.
48. Fishbane S., Kalantar-Zadeh K., Nissenson A.R. Serum ferritin in chronickidney disease: reconsidering the upper limit for iron treatment // Semin Dial. 2004. Vol. 17. P. 336–341.
49. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines forAnemia of Chronic Kidney Disease: update 2000 // Am J Kidney Dis. 2001. Vol. 37. S182–S238.
50. National Kidney Foundation. KDOQI Clinical Practice Guidelines andClinical Practice Recommendations for Anemia in Chronic KidneyDisease // Am J Kidney Dis. 2006. Vol. 47. S1–S146.
51. National Kidney Foundation. KDOQI Clinical Practice Guideline andClinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target // Am J Kidney Dis. 2007. Vol. 50. P. 471–530.
52. Locatelli F., Covic A., Eckardt K.U. et al. Anaemia management in patientswith chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP) // Nephrol Dial Transplant. 2009. Vol. 24. P. 348–354.
53. Coyne D.W., Kapoian T., Suki W. et al. Ferric gluconate is highly efficaciousin anemic hemodialysis patients with high serum ferritin and lowtransferrin saturation: results of the Dialysis Patients0 Response to IV Ironwith Elevated Ferritin (DRIVE) Study // J. Am. Soc. Nephrol. 2007. Vol. 18. P. 975–984.
54. Canavese C., Bergamo D., Ciccone G. et al. Validation of serum ferritinvalues by magnetic susceptometry in predicting iron overload in dialysispatients // Kidney Int. 2004. Vol. 65. P. 1091–1098.
55. Ferrari P., Kulkarni H., Dheda S. et al. Serum iron markers are inadequatefor guiding iron repletion in chronic kidney disease // Clin. J. Am. Soc. Nephrol. 2011. Vol. 6. P. 77–83.
56. Caramelo C., Albalate M., Bermejillo T. et al. Relationships between plasmaferritin and aminotransferase profile in haemodialysis patients withhepatitis C virus // Nephrol Dial Transplant. 1996. Vol. 11. P. 1792–1796.
57. Morrison E.D., Brandhagen D.J., Phatak P.D. et al. Serum ferritin levelpredicts advanced hepatic fibrosis among U.S. patients with phenotypichemochromatosis // Ann Intern Med. 2003. Vol. 138. P. 627–633.
58. National Kidney Foundation. KDOQI Clinical Practice Guidelines andClinical Practice Recommendations for Anemia in Chronic KidneyDisease. Section III. Clinical practice recommendations for anemiain chronic kidney disease in children // Am J Kidney Dis. 2006. Vol. 47. S. 86–108.
59. Agarwal R., Rizkala A.R., Bastani B. et al. A randomized controlled trial oforal versus intravenous iron in chronic kidney disease // Am J Nephrol. 2006. Vol. 26. P. 445–454.
60. Aggarwal H.K., Nand N., Singh S. et al. Comparison of oral versusintravenous iron therapy in predialysis patients of chronic renal failurereceiving recombinant human erythropoietin // J Assoc Physicians India. 2003. Vol. 51. P. 170–174.
61. Charytan C., Qunibi W., Bailie G.R. Comparison of intravenous iron sucroseto oral iron in the treatment of anemic patients with chronic kidneydisease not on dialysis // Nephron Clin Pract. 2005. Vol. 100. c55–c62.
62. Rozen-Zvi B., Gafter-Gvili A., Paul M. et al. Intravenous versus oral ironsupplementation for the treatment of anemia in CKD: systematic reviewand meta-analysis // Am J Kidney Dis. 2008. Vol. 52. P. 897–906.
63. Stoves J., Inglis H., Newstead C.G. A randomized study of oral vsintravenous iron supplementation in patients with progressive renalinsufficiency treated with erythropoietin // Nephrol Dial Transplant. 2001. Vol. 16. P. 967–974.
64. Allegra V., Mengozzi G., Vasile A. Iron deficiency in maintenancehemodialysis patients: assessment of diagnosis criteria and of threedifferent iron treatments // Nephron. 1991. Vol. 57. P. 175–182.
65. Li H., Wang S.X. Intravenous iron sucrose in Chinese hemodialysispatients with renal anemia // Blood Purif. 2008. Vol. 26. P. 151–156.
66. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron intreatment of anemia in peritoneal dialysis patients: a single centercomparative study // J. Am. Soc. Nephrol. 1998. Vol. 9. P. 664–668.
67. Johnson D.W., Herzig K.A., Gissane R. et al. A prospective crossover trialcomparing intermittent intravenous and continuous oral ironsupplements in peritoneal dialysis patients // Nephrol Dial Transplant. 2001. Vol. 16. P. 1879–1884.
68. Johnson D.W., Herzig K.A., Gissane R. et al. Oral versus intravenous ironsupplementation in peritoneal dialysis patients // Perit Dial Int. 2001. Vol. 21 (Suppl 3). S231–S235.
69. Li H., Wang S.X. Intravenous iron sucrose in peritoneal dialysis patientswith renal anemia // Perit Dial Int. 2008. Vol. 28. P. 149–154.
70. Singh H., Reed J., Noble S. et al. Effect of intravenous iron sucrose inperitoneal dialysis patients who receive erythropoiesis-stimulatingagents for anemia: a randomized, controlled trial // Clin. J. Am. Soc. Nephrol. 2006. Vol. 1. P. 475–482.
71. Eschbach J.W., Cook J.D., Scribner B.H. et al. Iron balance in hemodialysispatients // Ann Intern Med. 1977. Vol. 87. P. 710–713.
72. Sargent J.A., Acchiardo S.R. Iron requirements in hemodialysis // Blood Purif. 2004. Vol. 22. P. 112–123.
73. Schaefer R.M., Schaefer L. Iron monitoring and supplementation: how dowe achieve the best results? // Nephrol Dial Transplant. 1998. Vol. 13 (Suppl 2). P. 9–12.
74. Besarab A., Amin N., Ahsan M. et al. Optimization of epoetin therapy withintravenous iron therapy in hemodialysis patients // J. Am. Soc. Nephrol. 2000. Vol. 11. P. 530–538.
75. Ruiz-Jaramillo Mde L., Guizar-Mendoza J.M., Gutierrez-Navarro Mde J. et al. Intermittent versus maintenance iron therapy in children onhemodialysis: a randomized study // Pediatr Nephrol. 2004. Vol. 19. P. 77–81.
76. Schroder C.H. The management of anemia in pediatric peritoneal dialysispatients. Guidelines by an ad hoc European committee // Pediatr Nephrol. 2003. Vol. 18. P. 805–809.
77. Van Damme-Lombaerts R., Herman J. Erythropoietin treatment inchildren with renal failure // Pediatr Nephrol. 1999. Vol. 13. P. 148–152.
78. Warady B.A., Kausz A., Lerner G. et al. Iron therapy in the pediatrichemodialysis population // Pediatr Nephrol. 2004. Vol. 19. P. 655–661.
79. Warady B.A., Zobrist R.H., Wu J. et al. Sodium ferric gluconate complextherapy in anemic children on hemodialysis // Pediatr Nephrol. 2005. Vol. 20. P. 1320–1327.
80. Warady B.A., Zobrist R.H., Finan E. Sodium ferric gluconate complexmaintenance therapy in children on hemodialysis // Pediatr Nephrol. 2006. Vol. 21. P. 553–560.
81. Anbu A.T., Kemp T., OoDonnell K. et al. Low incidence of adverse eventsfollowing 90-minute and 3-minute infusions of intravenous iron sucrosein children on erythropoietin // ActaPaediatr. 2005. Vol. 94. P. 1738–1741.
82. Bailie G.R., Clark J.A., Lane C.E. et al. Hypersensitivity reactions and deathsassociated with intravenous iron preparations // Nephrol Dial Transplant. 2005. Vol. 20. P. 1443–1449.
83. Charytan C., Schwenk M.H., Al-Saloum M.M. et al. Safety of iron sucrose inhemodialysis patients intolerant to other parenteral iron products // Nephron Clin Pract. 2004. Vol. 96. c63–c66.
84. Fishbane S., Ungureanu V.D., Maesaka J.K. et al. The safety of intravenousiron dextran in hemodialysis patients // Am J Kidney Dis. 1996. Vol. 28. P. 529–534.
85. Fletes R., Lazarus J.M., Gage J. et al. Suspected iron dextran-relatedadverse drug events in hemodialysis patients // Am J Kidney Dis. 2001. Vol. 37. P. 743–749.
86. Jain A.K., Bastani B. Safety profile of a high dose ferric gluconate inpatients with severe chronic renal insufficiency // J Nephrol. 2002. Vol. 15. P. 681–683.
87. Lu M., Cohen M.H., Rieves D. et al. FDA report: Ferumoxytol forintravenous iron therapy in adult patients with chronic kidney disease // Am J Hematol. 2010. Vol. 85. P. 315–319.
88. Macdougall I.C., Roche A. Administration of intravenous iron sucrose as a2-minute push to CKD patients: a prospective evaluation of injections // Am J Kidney Dis. 2005. Vol. 46. P. 283–289.
89. Michael B., Coyne D.W., Fishbane S. et al. Sodium ferric gluconate complexin hemodialysis patients: adverse reactions compared to placebo andiron dextran // Kidney Int. 2002. Vol. 61. P. 1830–1839.
90. Sav T., Tokgoz B., Sipahioglu M.H. et al. Is there a difference between theallergic potencies of the iron sucrose and low molecular weight irondextran? // Ren Fail. 2007. Vol. 29. P. 423–426.
91. Ullian M.E., Gadegbeku C.A. Effects of intravenously administered iron onsystemic blood pressure in hemodialysis patients // Nephron Clin Pract. 2004. Vol. 98. P. c83–c86.
92. Auerbach M., Al Talib K. Low-molecular weight iron dextran and ironsucrose have similar comparative safety profiles in chronic kidneydisease // Kidney Int. 2008. Vol. 73. P. 528–530.
93. Chertow G.M., Mason P.D., Vaage-Nilsen O. et al. On the relative safety ofparenteral iron formulations // Nephrol Dial Transplant. 2004. Vol. 19. P. 1571–1575.
94. Chertow G.M., Mason P.D., Vaage-Nilsen O. et al. Update on adverse drugevents associated with parenteral iron // Nephrol Dial Transplant. 2006. Vol. 21. P. 378–382.
95. McCarthy J.T., Regnier C.E., Loebertmann C.L. et al. Adverse events inchronic hemodialysis patients receiving intravenous iron dextran–acomparison of two products // Am J Nephrol. 2000. Vol. 20. P. 455–462.
96. Rodgers G.M., Auerbach M., Cella D. et al. High-molecular weight irondextran: a wolf in sheepos clothing? // J Am SocNephrol. 2008. Vol. 19. P. 833–834.
97. Wessling-Resnick M. Iron homeostasis and the inflammatory response // Annu Rev Nutr. 2010. Vol. 30. P. 105–122.
98. Appelberg R. Macrophage nutriprive antimicrobial mechanisms // J Leukoc Biol. 2006. Vol. 79. P. 1117–1128.
99. Byrd T.F., Horwitz M.A. Interferon gamma-activated human monocytesdownregulate transferrin receptors and inhibit the intracellularmultiplication of Legionella pneumophila by limiting the availability ofiron // J Clin Invest. 1989. Vol. 83. P. 1457–1465.
100. Mencacci A., Cenci E., Boelaert J.R. et al. Iron overload alters innate and Thelper cell responses to Candida albicans in mice // J Infect Dis. 1997. Vol. 175. P. 1467–1476.
101. Nairz M., Theurl I., Ludwiczek S. et al. The co-ordinated regulation of ironhomeostasis in murine macrophages limits the availability of iron forintracellular Salmonella typhimurium // Cell Microbiol. 2007. Vol. 9. P. 2126–2140.
102. Hoen B., Paul-Dauphin A., Hestin D. et al. EPIBACDIAL: a multicenterprospective study of risk factors for bacteremia in chronic hemodialysispatients // J. Am. Soc. Nephrol. 1998. Vol. 9. P. 869–876.
103. Hoen B., Paul-Dauphin A., Kessler M. Intravenous iron administrationdoes not significantly increase the risk of bacteremia in chronichemodialysis patients // Clin Nephrol. 2002. Vol. 57. P. 457–461.
104. Teehan G.S., Bahdouch D., Ruthazer R. et al. Iron storage indices: novelpredictors of bacteremia in hemodialysis patients initiating intravenousiron therapy // Clin Infect Dis. 2004. Vol. 38. P. 1090–1094.
105. Bernhardt W.M., Wiesener M.S., Scigalla P. et al. Inhibition of prolylhydroxylases increases erythropoietin production in ESRD // J. Am. Soc. Nephrol. 2010. Vol. 21. P. 2151–2156.
106. Goodnough L.T., Brecher M.E., Kanter M.H. et al. Transfusion medicine.Firstof two parts–blood transfusion // N Engl J Med. 1999. Vol. 340. P. 438–447.
107. MacLeod A.M. The blood transfusion effect: clinical aspects // Immunol Lett. 1991. Vol. 29. P. 123–126.
108. Shander A., Sazama K. Clinical consequences of iron overload fromchronic red blood cell transfusions, its diagnosis, and its managementby chelation therapy // Transfusion. 2010. Vol. 50. P. 1144–1155.
109. Zhou Y.C., Cecka J.M. Sensitization in renal transplantation // Clin Transpl. 1991. P. 313–323.
110. Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass index increasein early renal disease: impact of decline in hemoglobin // Am J Kidney Dis. 1999. Vol. 34. P. 125–134.
111. Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia oncardiomyopathy, morbidity, and and mortality in end-stage renaldisease // Am J Kidney Dis. 1996. Vol. 28. P. 53–61.
112. Harnett J.D., Foley R.N., Kent G.M. et al. Congestive heart failure in dialysispatients: prevalence, incidence, prognosis and risk factors // Kidney Int. 1995. Vol. 47. P. 884–890.
113. Rigatto C., Parfrey P., Foley R. et al. Congestive heart failure in renaltransplant recipients: risk factors, outcomes, and relationship with ischemic heart disease // J. Am. Soc. Nephrol. 2002. Vol. 13. P. 1084–1090.
114. Collins A.J. Influence of target hemoglobin in dialysis patients onmorbidity and mortality // Kidney Int Suppl. 2002. P. 44–48.
115. Ofsthun N., Labrecque J., Lacson E. et al. The effects of higher hemoglobinlevels on mortality and hospitalization in hemodialysis patients // Kidney Int. 2003. Vol. 63. P. 1908–1914.
116. Regidor D.L., Kopple J.D., Kovesdy C.P. et al. Associations between changesin hemoglobin and administered erythropoiesis-stimulating agent andsurvival in hemodialysis patients // J. Am. Soc. Nephrol. 2006. Vol. 17. P. 1181–1191.
117. Goodkin D.A., Fuller D.S., Robinson B.M. et al. Naturally occurring higherhemoglobin concentration does not increase mortality amonghemodialysis patients // J. Am. Soc. Nephrol. 2011. Vol. 22. P. 358–365.
118. Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal ascompared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin // N Engl J Med. 1998. Vol. 339. P. 584–590.
119. Parfrey P.S., Wish T. Quality of life in CKD patients treated witherythropoiesis-stimulating agents // Am J Kidney Dis. 2010. Vol. 55. P. 423–425.
120. Lietz K., Lao M., Paczek L. et al. The impact of pretransplant erythropoietintherapy on late outcomes of renal transplantation // Ann Transplant. 2003. Vol. 8. P. 17–24.
121. Choukroun G., Kamar N., Dussol B. et al. Correction of postkidneytransplant anemia reduces progression of allograft nephropathy // J. Am. Soc. Nephrol. 2012. Vol. 23. P. 360–368.
122. Canadian Erythropoietin Study Group. Association betweenrecombinant human erythropoietin and quality of life and exercisecapacity of patients receiving haemodialysis // BMJ. 1990. Vol. 300. P. 573–578.
123. Revicki D.A., Brown R.E., Feeny D.H. et al. Health-related quality of lifeassociated with recombinant human erythropoietin therapy forpredialysis chronic renal disease patients // Am J Kidney Dis. 1995. Vol. 25. P. 548–554.
124. Drueke T.B., Locatelli F., Clyne N. et al. Normalization of hemoglobin levelin patients with chronic kidney disease and anemia // N Engl J Med. 2006. Vol. 355. P. 2071–2084.
125. Furuland H., Linde T., Ahlmen J. et al. A randomized controlled trial ofhaemoglobin normalization with epoetinalfa in pre-dialysis and dialysispatients // Nephrol Dial Transplant. 2003. Vol. 18. P. 353–361.
126. Parfrey P.S., Foley R.N., Wittreich B.H. et al. Double-blind comparison of fulland partial anemia correction in incident hemodialysis patients withoutsymptomatic heart disease // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2180–2189.
127. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al. A trial of darbepoetinalfa intype 2 diabetes and chronic kidney disease // N Engl J Med. 2009. Vol. 361. P. 2019–2032.
128. Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetinalfa in chronic kidney disease // N Engl J Med. 2006. Vol. 355. P. 2085–2098.
129. Foley R.N., Curtis B.M., Parfrey P.S. Hemoglobin targets and bloodtransfusions in hemodialysis patients without symptomatic cardiacdisease receiving erythropoietin therapy // Clin. J. Am. Soc. Nephrol. 2008. Vol. 3. P. 1669–1675.
130. Foley R.N., Curtis B.M., Parfrey P.S. Erythropoietin therapy, hemoglobintargets, and quality of life in healthy hemodialysis patients: a randomized trial // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. P. 726–733.
131. FDA presentation at Cardiovascular and Renal Drugs AdvisoryCommittee (CRDAC) meeting, 18 October 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM231978.pdf.
132. Lewis E.F., Pfeffer M.A., Feng A. et al. Darbepoetinalfa impact on healthstatus in diabetes patients with kidney disease: a randomized trial // Clin. J. Am. Soc. Nephrol. 2011. Vol. 6. P. 845–855.
133. Palmer S.C., Navaneethan S.D., Craig J.C. et al. Meta-analysis: erythropoiesisstimulatingagents in patients with chronic kidney disease // Ann Intern Med. 2010. Vol. 153. P. 23–33.
134. Gandra S.R., Finkelstein F.O., Bennett A.V. et al. Impact of erythropoiesisstimulatingagents on energy and physical function in nondialysis CKDpatients with anemia: a systematic review // Am J Kidney Dis 2010; 55:519–534.
135. Johansen K.L., Finkelstein F.O., Revicki D.A. et al. Systematic review andmeta-analysis of exercise tolerance and physical functioning in dialysispatients treated with erythropoiesis-stimulating agents // Am J Kidney Dis. 2010. Vol. 55. P. 535–548.
136. Rizzo J.D., Brouwers M., Hurley P. et al. American Society of ClinicalOncology/American Society of Hematology clinical practice guidelineupdate on the use of epoetin and darbepoetin in adult patients with cancer // J Clin Oncol. 2010. Vol. 28. P. 4996–5010.
137. Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline updateon the use of epoetin and darbepoetin in adult patients with cancer // Blood. 2010. Vol. 116. P. 4045–4059.
138. Skali H., Parving H.H., Parfrey P.S. et al. Stroke in patients with type 2diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesptherapy (TREAT) experience // Circulation. 2011. Vol. 124. P. 2903–2908.
139. Warady B.A., Ho M. Morbidity and mortality in children with anemia atinitiation of dialysis // Pediatr Nephrol. 2003. Vol. 18. P. 1055–1062.
140. Mitsnefes M.M., Kimball T.R., Kartal J. et al. Progression of left ventricularhypertrophy in children with early chronic kidney disease: 2-year followupstudy // J Pediatr. 2006. Vol. 149. P. 671–675.
141. Schaefer F. Cardiac disease in children with mild-to-moderate chronickidney disease // Curr Opin Nephrol Hypertens. 2008. Vol. 17. P. 292–297.
142. Morris K.P., Sharp J., Watson S. et al. Non-cardiac benefits of humanrecombinant erythropoietin in end stage renal failure and anaemia // Arch Dis Child. 1993. Vol. 69. P. 580–586.
143. Gerson A., Hwang W., Fiorenza J. et al. Anemia and health-related qualityof life in adolescents with chronic kidney disease // Am J Kidney Dis. 2004. Vol. 44. P. 1017–1023.
144. Staples A.O., Wong C.S., Smith J.M. et al. Anemia and risk of hospitalizationin pediatric chronic kidney disease // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. P. 48–56.
145. Solomon S.D., Uno H., Lewis E.F. et al. Erythropoietic response andoutcomes in kidney disease and type 2 diabetes // N Engl J Med. 2010. Vol. 363. P. 1146–1155.
146. Fishbane S., Berns J.S. Hemoglobin cycling in hemodialysis patientstreated with recombinant human erythropoietin // Kidney Int. 2005. Vol. 68. P. 1337–1343.
147. Yang W., Israni R.K., Brunelli S.M. et al. Hemoglobin variability and mortalityin ESRD // J. Am. Soc. Nephrol. 2007. Vol. 18. P. 3164–3170.
148. Eckardt K.U., Kim J., Kronenberg F. et al. Hemoglobin variability does notpredict mortality in European hemodialysis patients // J. Am. Soc. Nephrol. 2010. Vol. 21. P. 1765–1775.
149. Kaufman J.S., Reda D.J., Fye C.L. et al. Subcutaneous compared withintravenous epoetin in patients receiving hemodialysis. Department ofVeterans Affairs Cooperative Study Group on Erythropoietin inHemodialysis Patients // N Engl J Med. 1998. Vol. 339. P. 578–583.
150. De Schoenmakere G., Lameire N., Dhondt A. et al. The haematopoieticeffect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.) // Nephrol Dial Transplant. 1998. Vol. 13. P. 1770–1775.
151. Chanu P., Gieschke R., Charoin J.E. et al. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treatedchronic kidney disease patients with renal anemia // J Clin Pharmacol. 2010. Vol. 50. P. 507–520.
152. Locatelli F., Canaud B., Giacardy F. et al. Treatment of anaemia in dialysispatients with unit dosing of darbepoetinalfa at a reduced dosefrequency relative to recombinant human erythropoietin (rHuEpo) // Nephrol Dial Transplant. 2003. Vol. 18. P. 362–369.
153. Vanrenterghem Y., Barany P., Mann J.F. et al. Randomized trial ofdarbepoetinalfa for treatment of renal anemia at a reduced dosefrequency compared with rHuEPO in dialysis patients // Kidney Int. 2002. Vol. 62. P. 2167–2175.
154. Locatelli F., Villa G., Messa P. et al. Efficacy and safety of once-weeklyintravenous epoetinalfa in maintaining hemoglobin levels inhemodialysis patients // J Nephrol. 2008. Vol. 21. P. 412–420.
155. Pergola P.E., Gartenberg G., Fu M. et al. A randomized controlled study ofweekly and biweekly dosing of epoetinalfa in CKD Patients withanemia // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. P. 1731–1740.
156. Carrera F., Lok C.E., de Francisco A. et al. Maintenance treatment of renalanaemia in haemodialysis patients with methoxy polyethylene glycolepoetinbeta versus darbepoetinalfa administered monthly: a randomizedcomparative trial // Nephrol Dial Transplant. 2010. Vol. 25. P. 4009–4017.
157. Gobin J., Cernii A., McLean R. et al. Conversion from epoetinalfa todarbepoetinalfa for management of anaemia in a community chronickidney disease centre: a retrospective cohort study // Clin Drug Investig. 2011. Vol. 31. P. 113–120.
158. Boven K., Stryker S., Knight J. et al. The increased incidence of pure redcell aplasia with an Eprex formulation in uncoated rubber stoppersyringes // Kidney Int. 2005. Vol. 67. P. 2346–2353.
159. Casadevall N., Nataf J., Viron B. et al. Pure red-cell aplasia andantierythropoietin antibodies in patients treated with recombinanterythropoietin // N Engl J Med. 2002. Vol. 346. P. 469–475.
160. Macdougall I.C., Ashenden M. Current and upcoming erythropoiesisstimulatingagents, iron products, and other novel anemia medications // Adv Chronic Kidney Dis. 2009. Vol. 16. P. 117–130.
161. Locatelli F., Baldamus C.A., Villa G. et al. Once-weekly compared withthree-times-weekly subcutaneous epoetin beta: results from arandomized, multicenter, therapeutic-equivalence study // Am J Kidney Dis. 2002. Vol. 40. P. 119–125.
162. Nissenson A.R., Swan S.K., Lindberg J.S. et al. Randomized, controlled trial ofdarbepoetinalfa for the treatment of anemia in hemodialysis patients // Am J Kidney Dis. 2002. Vol. 40. P. 110–118.
163. Tolman C., Richardson D., Bartlett C. et al. Structured conversion fromthrice weekly to weekly erythropoietic regimens using a computerizeddecision-support system: a randomized clinical study // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 1463–1470.
164. Kilpatrick R.D., Critchlow C.W., Fishbane S. et al. Greater epoetinalfaresponsiveness is associated with improved survival in hemodialysispatients // Clin. J. Am. Soc. Nephrol. 2008. Vol. 3. P. 1077–1083.
165. Greene T., Daugirdas J., Depner T. et al. Association of achieved dialysisdose with mortality in the hemodialysis study: an example of oodosetargetingbiasoo // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 3371–3380.
166. Koshy S.M., Geary D.F. Anemia in children with chronic kidney disease // Pediatr Nephrol. 2008. Vol. 23. P. 209–219.
167. Bamgbola O.F., Kaskel F.J., Coco M. Analyses of age, gender and other riskfactors of erythropoietin resistance in pediatric and adult dialysiscohorts // Pediatr Nephrol. 2009. Vol. 24. P. 571–579.
168. Szczech L.A., Barnhart H.X., Inrig J.K. et al. Secondary analysis of the CHOIRtrial epoetin-alpha dose and achieved hemoglobin outcomes // Kidney Int. 2008. Vol. 74. P. 791–798.
169. Brookhart M.A., Schneeweiss S., Avorn J. et al. Comparative mortality riskof anemia management practices in incident hemodialysis patients // JAMA. 2010. Vol. 303. P. 857–864.
170. Berns J.S., Rudnick M.R., Cohen R.M. A controlled trial of recombinant humanerythropoietin and nandrolonedecanoate in the treatment of anemia inpatients on chronic hemodialysis // Clin Nephrol. 1992. Vol. 37. P. 264–267.
171. Gaughan W.J., Liss K.A., Dunn S.R. et al. A 6-month study of low-doserecombinant human erythropoietin alone and in combination withandrogens for the treatment of anemia in chronic hemodialysis patients // Am J Kidney Dis. 1997. Vol. 30. P. 495–500.
172. Sheashaa H., Abdel-Razek W., El-Husseini A. et al. Use of nandrolonedecanoate as an adjuvant for erythropoietin dose reduction in treatinganemia in patients on hemodialysis // Nephron Clin Pract. 2005. Vol. 99. c102–c106.
173. Bridges K.R., Hoffman K.E. The effects of ascorbic acid on the intracellularmetabolism of iron and ferritin // J Biol.Chem. 1986. Vol. 261. P. 14273–14277.
174. Lipschitz D.A., Bothwell T.H., Seftel H.C. et al. The role of ascorbic acid in themetabolism of storage iron // Br J Haematol. 1971. Vol. 20. P. 155–163.
175. Deved V., Poyah P., James M.T. et al. Ascorbic acid for anemiamanagement in hemodialysis patients: a systematic review and meta-analysis // Am J Kidney Dis. 2009. Vol. 54. P. 1089–1097.
176. Shahrbanoo K., Taziki O. Effect of intravenous ascorbic acid inhemodialysis patients with anemia and hyperferritinemia // Saudi J Kidney Dis Transpl. 2008. Vol. 19. P. 933–936.
177. Attallah N., Osman-Malik Y., Frinak S. et al. Effect of intravenous ascorbicacid in hemodialysis patients with EPO-hyporesponsive anemia andhyperferritinemia // Am J Kidney Dis. 2006. Vol. 47. P. 644–654.
178. Sezer S., Ozdemir F.N., Yakupoglu U. et al. Intravenous ascorbic acidadministration for erythropoietin-hyporesponsive anemia in iron loadedhemodialysis patients // Artif Organs. 2002. Vol. 26. P. 366–370.
179. Rossert J., Casadevall N., Eckardt K.U. Anti-erythropoietin antibodies andpure red cell aplasia // J. Am. Soc. Nephrol. 2004. Vol. 15. P. 398–406.
180. Eckardt K.U., Casadevall N. Pure red-cell aplasia due to anti-erythropoietinantibodies // Nephrol Dial Transplant. 2003. Vol. 18. P. 865–869.
181. Shimizu H., Saitoh T., Ota F. et al. Pure red cell aplasia induced only byintravenous administration of recombinant human erythropoietin // Acta Haematol. 2011. Vol. 126. P. 114–118.
182. Casadevall N., Cournoyer D., Marsh J. et al. Recommendations onhaematological criteria for the diagnosis of epoetin-induced pure redcell aplasia // Eur J Haematol. 2004. Vol. 73. P. 389–396.
183. Cournoyer D., Toffelmire E.B., Wells G.A. et al. Anti-erythropoietinantibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations forminimization of risk // J. Am. Soc. Nephrol. 2004. Vol. 15. P. 2728–2734.
184. Macdougall I.C. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks // Nephrol Dial Transplant. 2005. Vol. 20 (Suppl 4). iv9–i15.
185. Verhelst D., Rossert J., Casadevall N. et al. Treatment of erythropoietininducedpure red cell aplasia: a retrospective study // Lancet. 2004. Vol. 363. P. 1768–1771.
186. Andrade J., Taylor P.A., Love J.M. et al. Successful reintroduction of adifferent erythropoiesis-stimulating agent after pure red cell aplasia:relapse after successful therapy with prednisone // Nephrol Dial Transplant. 2005. Vol. 20. P. 2548–2551.
187. Weber G., Gross J., Kromminga A. et al. Allergic skin and systemicreactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins // J. Am. Soc. Nephrol. 2002. Vol. 13. P. 2381–2383.
188. Macdougall I.C., Rossert J., Casadevall N. et al. A peptide-basederythropoietin-receptor agonist for pure red-cell aplasia // N Engl J Med. 2009. Vol. 361. P. 1848–1855.
189. Schellekens H. Biosimilar therapeutics-what do we need to consider? // NDT Plus. 2009. Vol. 2. i27–i36.
190. Opelz G., Graver B., Mickey M.R. et al. Lymphocytotoxic antibodyresponses to transfusions in potential kidney transplant recipients // Transplantation. 1981. Vol. 32. P. 177–183.
191. USRDS System. USRDS 2010 Annual Data Report: Atlas of Chronic KidneyDisease and End-Stage Renal Disease in the United States. NationalInstitutes of Health 2010, National Institute of Diabetes and Digestiveand Kidney Diseases.
192. Linman J.W. Physiologic and pathophysiologic effects of anemia // N Engl J Med. 1968. Vol. 279. P. 812–818.
193. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies:a prospective trial // Am J Transplant. 2004. Vol. 4. P. 438–443.
194. Terasaki P.I., Ozawa M. Predictive value of HLA antibodies and serumcreatinine in chronic rejection: results of a 2-year prospective trial // Transplantation. 2005. Vol. 80. P. 1194–1197.
195. Cid J., Ramiro L., Bertran S. et al. Efficacy in reducing potassium load inirradiated red cell bags with a potassium adsorption filter // Transfusion. 2008. Vol. 48. P. 1966–1970.
196. Dodd R. Managing the microbiological safety of blood fortransfusion: a US perspective // Future Microbiol. 2009. Vol. 4. P. 807–818.
197. Goodnough L.T., Shander A., Brecher M.E. Transfusion medicine: lookingto the future // Lancet. 2003. Vol. 361. P. 161–169.
198. Jacobs M.R., Palavecino E., Yomtovian R. Donot bug me: the problem ofbacterial contamination of blood components–challenges andsolutions // Transfusion. 2001. Vol. 41. P. 1331–1334.
199. Klein H. Mollisonos Blood Transfusion in Clinical Medicine, 11th edn. Wiley-Blackwell, 2005.
200. Kleinman S., Caulfield T., Chan P. et al. Toward an understanding oftransfusion-related acute lung injury: statement of a consensus panel // Transfusion. 2004. Vol. 44. P. 1774–1789.
201. Kuehnert M.J., Roth V.R., Haley N.R. et al. Transfusion-transmitted bacterialinfection in the United States, 1998 through 2000 // Transfusion. 2001. Vol. 41. P. 1493–1499.
202. Looney M.R., Gropper M.A., Matthay M.A. Transfusion-related acute lunginjury: a review // Chest. 2004. Vol. 126. P. 249–258.
203. Silliman C.C., Ambruso D.R., Boshkov L.K. Transfusion-related acute lunginjury // Blood. 2005. Vol. 105. P. 2266–2273.
204. Simon G.E., Bove J.R. The potassium load from blood transfusion // Postgrad Med. 1971. Vol. 49. P. 61–64.
205. Smith H.M., Farrow S.J., Ackerman J.D. et al. Cardiac arrests associated withhyperkalemia during red blood cell transfusion: a case series // Anesth Analg. 2008. Vol. 106. P. 1062–1069.
206. Stramer S.L., Hollinger F.B., Katz L.M. et al. Emerging infectious diseaseagents and their potential threat to transfusion safety // Transfusion. 2009. Vol. 49 (Suppl 2). 1S–29S.
207. Vasconcelos E., Seghatchian J. Bacterial contamination in bloodcomponents and preventative strategies: an overview // Transfus Apher Sci. 2004. Vol. 31. P. 155–163.
208. Cable R.G., Leiby D.A. Risk and prevention of transfusion-transmittedbabesiosis and other tick-borne diseases // Curr Opin Hematol. 2003. Vol. 10. P. 405–411.
209. Herwaldt B.L., Neitzel D.F., Gorlin J.B. et al. Transmission of Babesiamicrotiin Minnesota through four blood donations from the same donor over a6-month period // Transfusion. 2002. Vol. 42. P. 1154–1158.
210. Leiby D.A., Gill J.E. Transfusion-transmitted tick-borne infections: acornucopia of threats // Transfus Med Rev. 2004. Vol. 18. P. 293–306.
211. Wells G.M., Woodward T.E., Fiset P. et al. Rocky mountain spotted fevercaused by blood transfusion // JAMA. 1978. Vol. 239. P. 2763–2765.
212. Carson J.L., Grossman B.J., Kleinman S. et al. Red Blood Cell Transfusion: AClinical Practice Guideline From the AABB // Ann Intern Med. 2012 (in press).
213. Klein H.G. How safe is blood, really? // Biologicals. 2010. Vol. 38. P. 100–104.
214. Klein H.G., Spahn D.R., Carson J.L. Red blood cell transfusion in clinicalpractice // Lancet. 2007. Vol. 370. P. 415–426.
215. Rawn J. The silent risks of blood transfusion // Curr Opin Anaesthesiol. 2008. Vol. 21. P. 664–668.
216. Opelz G., Vanrenterghem Y., Kirste G. et al. Prospective evaluation ofpretransplant blood transfusions in cadaver kidney recipients // Transplantation. 1997. Vol. 63. P. 964–967.
217. Reed A., Pirsch J., Armbrust M.J. et al. Multivariate analysis ofdonor-specific versus random transfusion protocols in haploidenticalliving-related transplants // Transplantation. 1991. Vol. 51. P. 382–384.
218. Vanrenterghem Y., Waer M., Roels L. et al. A prospective, randomized trialof pretransplant blood transfusions in cadaver kidney transplantcandidates. Leuven Collaborative Group for Transplantation // Transpl Int. 1994. Vol. 7 (Suppl 1). S243–S246.
219. Christiaans M.H., van Hooff J.P., Nieman F. et al. HLA-DR matchedtransfusions: development of donor-specific T- and B-cell antibodies andrenal allograft outcome // Transplantation. 1999. Vol. 67. P. 1029–1035.
220. Cecka J.M., Cicciarelli J., Mickey M.R. et al. Blood transfusions and HLAmatching–an either/or situation in cadaveric renal transplantation // Transplantation. 1988. Vol. 45. P. 81–86.
221. Pfaff W.W., Howard R.J., Scornik J.C. et al. Incidental and purposeful randomdonor blood transfusion. Sensitization and transplantation // Transplantation. 1989. Vol. 47. P. 130–133.
222. Sanfilippo F., Vaughn W.K., Bollinger R.R. et al. Comparative effects ofpregnancy, transfusion, and prior graft rejection on sensitization andrenal transplant results // Transplantation. 1982. Vol. 34. P. 360–366.
223. Karpinski M., Pochinco D., Dembinski I. et al. Leukocyte reduction of redblood cell transfusions does not decrease allosensitization rates in potentialkidney transplant candidates // J. Am. Soc. Nephrol. 2004. Vol. 15. P. 818–824.
224. Sanfilippo F.P., Bollinger R.R., MacQueen J.M. et al. A randomized studycomparing leukocyte-depleted versus packed red cell transfusions inprospective cadaver renal allograft recipients // Transfusion. 1985. Vol. 25. P. 116–119.
225. Scornik J.C., Ireland J.E., Howard R.J. et al. Role of regular and leukocyte-freeblood transfusions in the generation of broad sensitization // Transplantation. 1984. Vol. 38. P. 594–598.
226. Balasubramaniam G.S., Morris M., Gupta A. et al. Allosensitization rate ofmale patients awaiting first kidney grafts after leuko-depleted bloodtransfusion // Transplantation. 2012. Vol. 93. P. 418–422.
227. Everett E.T., Kao K.J., Scornik J.C. Class I HLA molecules on humanerythrocytes. Quantitation and transfusion effects // Transplantation. 1987. Vol. 44. P. 123–129.
228. Oniscu G.C., Brown H., Forsythe J.L. Impact of cadaveric renaltransplantation on survival in patients listed for transplantation // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 1859–1865.
229. Port F.K., Wolfe R.A., Mauger E.A. et al. Comparison of survival probabilitiesfor dialysis patients vs cadaveric renal transplant recipients // JAMA. 1993. Vol. 270. P. 1339–1343.
230. Agarwal R. Individualizing decision-making–resurrecting the doctorpatientrelationship in the anemia debate // Clin. J. Am. Soc. Nephrol. 2010. Vol. 5. P. 1340–1346.
231. Cecka J.M., Cho L. Sensitization // Clin Transpl. 1988. P. 365–373.
232. Opelz G. Non-HLA transplantation immunity revealed bylymphocytotoxic antibodies // Lancet. 2005. Vol. 365. P. 1570–1576.
233. Lefaucheur C., Loupy A., Hill G.S. et al. Preexisting donor-specific HLAantibodies predict outcome in kidney transplantation // J. Am. Soc. Nephrol. 2010. Vol. 21. P. 1398–1406.
234. Murphy M.F., Wallington T.B., Kelsey P. et al. Guidelines for the clinical useof red cell transfusions // Br J Haematol. 2001. Vol. 113. P. 24–31.
235. Anderson J.L., Adams C.D., Antman E.M. et al. ACC/AHA 2007 guidelines forthe management of patients with unstable angina/non-ST-Elevationmyocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (WritingCommittee to Revise the 2002 Guidelines for the Management ofPatients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)developed in collaboration with the American College of EmergencyPhysicians, the Society for Cardiovascular Angiography andInterventions, and the Society of Thoracic Surgeons endorsed by theAmerican Association of Cardiovascular and Pulmonary Rehabilitationand the Society for Academic Emergency Medicine // J. Am. Coll. Cardiol. 2007. Vol. 50. e1–e157.
236. Harrington R.A., Becker R.C., Cannon C.P. et al. Antithrombotic therapy fornon-ST-segment elevation acute coronary syndromes: AmericanCollege of Chest Physicians Evidence-Based Clinical PracticeGuidelines (8th edn) // Chest. 2008. Vol. 133. 670S–707S.
237. Sabatine M.S., Morrow D.A., Giugliano R.P. et al. Association of hemoglobinlevels with clinical outcomes in acute coronary syndromes // Circulation. 2005. Vol. 111. P. 2042–2049.
238. Heart Failure Society of America. Nonpharmacologic management andhealth care maintenance in patients with chronic heart failure // J Card Fail. 2006. Vol. 12. e29–e37.
239. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC Guidelines for thediagnosis and treatment of acute and chronic heart failure 2012: TheTask Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed incollaboration with the Heart Failure Association (HFA) of the ESC. EurHeart J; e-pub ahead of print 19 May 2012.
240. Hunt S.A., Abraham W.T., Chin M.H. et al. 2009 Focused updateincorporated into the ACC/AHA 2005 Guidelines for the Diagnosis andManagement of Heart Failure in Adults A Report of the AmericanCollege of Cardiology Foundation/American Heart Association TaskForce on Practice Guidelines Developed in Collaboration With theInternational Society for Heart and Lung Transplantation // J. Am. Coll. Cardiol. 2009. Vol. 53. e1–e90.
241. Atkins D., Best D., Briss P.A. et al. Grading quality of evidence and strengthof recommendations // BMJ. 2004. Vol. 328. P. 1490.
242. Guyatt G.H., Oxman A.D., Kunz R. et al. Going from evidence torecommendations // BMJ. 2008. Vol. 336. P. 1049–1051.
243. Uhlig K., Macleod A., Craig J. et al. Grading evidence andrecommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving GlobalOutcomes (KDIGO) // Kidney Int. 2006. Vol. 70. P. 2058–2065.
244. The AGREE Collaboration. Development and validation of aninternational appraisal instrument for assessing the quality of clinicalpractice guidelines: the AGREE project // QualSaf Health Care. 2003. Vol. 12. P. 18–23.
245. Shiffman R.N., Shekelle P., Overhage J.M. et al. Standardized reporting ofclinical practice guidelines: a proposal from the Conference onGuideline Standardization // Ann Intern Med. 2003. Vol. 139. P. 493–498.
246. Institute of Medicine. Finding What Works in Health Care: Standards forSystematic Reviews. The National Academies Press: Washington, DC, 2011.
247. Institute of Medicine. Clinical Practice Guidelines We Can Trust. The National Academies Press: Washington, DC, 2011.

Другие статьи по теме

• Острое почечное повреждение Клинические практические рекомендации KDIGO (Основные положения)
• Клинические практические рекомендации KDIGO по лечению гломерулонефритов
• Клинические Практические Рекомендации KDIGO по Ведению Дислипидемии у Пациентов с Хронической Болезнью Почек
• Клинические Практические Рекомендации KDIGO 2012 по Диагностике и Лечению Хронической Болезни Почек